Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-10-01 / Anticancer Res 2020 Oct;40(10):5765-5776Pilot study on outcome and antitumor efficacy of an autologous cancer cell vaccine applied in patients with advanced solid tumors.
/in Dendritic Cells, International Publications /von 2020-08-31 / J Clin Oncol 38: 2020 (suppl; abstr 3000)The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2020-08-13 / Immunotherapy 2020 Aug;A dendritic cell multitasks to tackle cancer
/in Dendritic Cells, International Publications /von 2020-08-12 / Nature 2020 Aug;Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study
/in Cervical Cancer, Dendritic Cells, Endometrial Cancer, International Publications /von 2020-08-01 / Anticancer Res 2020 Aug;40(8):4729-4740Advanced clinical trials of dendritic cell vaccines in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-27 / J. Investig. Med. 2020 Jul;Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2020-07-27 / Ther Apher Dial 2020 Oct;24(5):482-491Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
/in Dendritic Cells, International Publications /von 2020-07-14 / Pharmaceutics 2020 Jul;12(7)Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-13 / Immunol. Invest. 2020 Jul;:1-18
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution